Nexium Buyers Win Class Cert In AstraZeneca Antitrust MDL

Law360, Los Angeles (November 14, 2013, 9:51 PM ET) -- A Massachusetts federal judge certified a class of Nexium end-buyers on Thursday who accused AstraZeneca PLC and others of violating antitrust laws by delaying a generic version of AstraZeneca’s heartburn drug, ruling the class met adequacy and predominance requirements.

In the multidistrict litigation, the judge certified a damages class consisting of an unidentified number of individual consumers, third-party payors, union plan sponsors and insurance companies that bought or provided reimbursements for Nexium in more than 20 states and the District of Columbia. The class period will...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required

Case Information

Case Title

In Re: Nexium (Esomeprazole) Antitrust Litigation

Case Number

1:12-md-02409

Court

Massachusetts

Nature of Suit

Anti-Trust

Judge

William G. Young

Law360 Coverage

Date Filed

December 7, 2012

Sections

Law Firms Mentioned

Companies Mentioned

Related Articles